The results showed that the serum AFP level in the treatment group was lower than that in the control group by 0.36 standard deviation units, which may reflect a positive impact on tumor burden or activity in patients with PLC (SMD = -0.36, 95% CI: −0.58 to −0.14, P = .002), with a statistically significant difference. The gene discussed is AFP; the disease is neoplasm.